Chad E. Beyer
Chad E. Beyer, PhD, MBA is CEO of Kures, Inc, a clinical-stage company focused on addiction. With more than 25 years of experience, Dr. Beyer is a drug hunter with a successful record of discovering and developing disease-modifying medications. Hewas formerly CEO and SVP of R&D at Promentis Pharmaceuticals and the Head of Neurochemistry at Wyeth Pharmaceuticals. Dr. Beyer has led numerous preclinical and clinical teams, participated in the submission of 33 INDs, and contributed to the commercialization of two blockbuster medications: Effexor® and Pristiq®. Dr. Beyer holds a Ph.D. in Pharmacology from LSU Medical Center and an MBA from the Rutgers Business School and has served on the Board of Directors of various companies. Notably, Dr. Beyer has authored more than 70 manuscripts, co-edited the book entitled “Next Generation Antidepressants, co-founded the journal “Technology Transfer & Entrepreneurship, and is an Entrepreneur in Residence at Lafayette College.
An OTP has been sent to your Registered Email Id:
Resend Verification Code
Hi! I'm Vidya, your virtual assistant.
Need a book recommendation, help with your order or support with any query? I’m here to assist you.
